Non-alcoholic fatty liver disease is a chronic metabolic disorder characterized by excessive fat accumulation in hepatocytes without alcohol consumption or another identifiable cause. An international multi-society consensus introduced the term metabolic dysfunction-associated steatotic liver disease in 2023, although the review retains the NAFLD abbreviation because much of the cited literature uses that terminology. The source estimates that NAFLD affects approximately 20% to 40% of populations in Western countries and 5% to 40% of the general population in the Asia-Pacific region. Its development is strongly associated with obesity, particularly abdominal obesity, insulin resistance and dietary habits, including high consumption of refined carbohydrates and saturated lipids.

The review describes a two-hit framework for the onset and progression of NAFLD. The first hit is insulin resistance, which impairs insulin-mediated suppression of hepatic glucose production and is associated with fatty-acid accumulation in hepatocytes. The second involves oxidation of accumulated fat and the production of metabolic by-products such as free radicals, which can promote hepatocyte damage and inflammation. Lipotoxicity, oxidative stress, mitochondrial damage, stellate-cell activation and fibrogenic signaling are also linked to progression from steatosis toward fibrosis and cirrhosis. These mechanisms identify possible points at which crop-derived constituents might act, but they do not demonstrate that eating a particular grain, oil or legume will prevent disease in an individual.

Rather than treating cereals and legumes as containers for single nutrients, the review examines them as whole-food matrices containing proteins, amino acids, fiber, lipids, phenolics, vitamins and minerals that may interact. Rice, barley, wheat, soybeans, adzuki beans, corn, sorghum and millets differ substantially in these constituents. Oats and barley are major sources of soluble β-glucan, while sorghum and millets contain diverse phenolic compounds; soybean and adzuki bean combine proteins, branched-chain amino acids, fiber and phytochemicals. Crop species, cultivars, growing environments, harvest conditions and processing can alter ingredient concentrations, bioaccessibility and biological activity. In one high-fat-diet mouse experiment, a whole corn-common bean formulation attenuated hepatic steatosis and reduced serum cholesterol and triglycerides while changing hepatic gene expression related to lipid metabolism, although such whole-food evidence remains limited.

Branched-chain amino acids demonstrate why concentration alone cannot define a crop’s metabolic effect. Soybean generally contains more protein and leucine, isoleucine and valine than cereal grains, while cereal matrices provide comparatively little of these amino acids alongside more fiber and phenolics. In animal models, administering 2% BCAAs in drinking water for eight weeks reduced hepatic triglycerides and serum aminotransferases in mice with diet-induced nonalcoholic steatohepatitis; another long-term mouse experiment reported reduced steatosis, inflammation and fibrosis, with liver-tumor incidence falling from 73.5% to 30.8%. Human findings are less straightforward. High circulating BCAA levels have been associated with adverse liver features in patients with biopsy-proven NAFLD or NASH, and a randomized exercise study found that reductions in circulating BCAAs were associated with lower liver fat independently of changes in body-mass index or insulin resistance. The review cautions that elevated blood BCAA concentrations can reflect impaired amino-acid catabolism rather than greater dietary intake, so these associations cannot be equated with the effects of eating protein-rich crops.

Fatty-acid evidence similarly depends on the balance of fatty acids and the surrounding dietary context. Soybean is relatively lipid-rich and supplies polyunsaturated fatty acids, including linoleic and α-linolenic acids, whereas sorghum and millet generally contain less total lipid but have profiles dominated by linoleic acid. Population studies have associated higher n-3 and n-6 polyunsaturated fatty acid intake with lower odds of NAFLD, although the direction and magnitude of these associations differ across populations. In experimental models, foxtail-millet oil reduced hepatic lipid accumulation and improved glucose and lipid metabolism while downregulating lipogenic genes and affecting AMPK–PPAR signaling, gut microbiota and bile-acid metabolism. Other animal experiments found that trans-fat-rich and oxidized-oil diets increased hepatic lipid peroxidation, suppressed antioxidant enzyme activity and promoted hepatocyte ballooning and necroinflammation. These findings show that processing can alter the biological character of crop-derived lipids, but they remain preclinical observations rather than clinical benefits.

Phenolic compounds add further complexity because their abundance and composition vary with species, cultivar, environment and post-harvest handling. Sorghum and millets contain phenolic acids, tannins, flavonoids and anthocyanins, while soybean is a major source of isoflavones. A randomized placebo-controlled trial reported that a supplement providing 100 mg of soy isoflavones per day for 12 weeks lowered serum triglycerides, low-density lipoprotein cholesterol, total cholesterol and some anthropometric indices in patients with NAFLD. Preclinical studies offer a different level of evidence. In mouse models, bound foxtail-millet polyphenols improved NAFLD-related phenotypes while changing gut microbiota composition, intestinal-barrier integrity and short-chain fatty acid production. Sorghum-bran polyphenols and extruded sorghum flour also reduced hepatic steatosis or systemic hyperlipidemia in obese animals. Such compound, extract or concentrated-product results may not predict the response to intact grain, because fiber, proteins, lipids, minerals and other constituents can alter phenolic absorption and microbial metabolism.

Dietary fiber provides a route connecting food composition with the gut–liver axis. Soluble and fermentable fiber can delay carbohydrate absorption, attenuate post-meal glucose excursions and suppress hepatic de novo lipogenesis. Colonic microbes convert fermentable substrates into short-chain fatty acids, including propionate and butyrate, which can support intestinal-barrier integrity, inhibit inflammatory signaling and promote hepatic fatty-acid oxidation. In high-fat-diet-fed mice, soluble millet-bran fiber reduced hepatic triglyceride and cholesterol accumulation, increased short-chain fatty acid production, activated PPARα and suppressed SREBP-1c; fermented millet fiber produced greater metabolic benefits than unfermented fiber. A systematic review and meta-analysis integrating preclinical and clinical studies reported improvements in liver enzymes, hepatic lipid indices and oxidative-stress markers with soybean and soybean-based foods. The effect cannot be assigned to fiber alone, however, because soy compounds operate within a matrix containing protein, lipids and phytochemicals.

Major obstacles prevent the available signals from becoming dietary guidance. Many experiments use purified compounds, extracts or supplements, while doses, intervention periods, models and outcome measures vary widely. Whole foods also change during milling, extrusion, thermal treatment, fermentation and storage. Excessive heat or high-shear processing can denature and aggregate proteins, alter digestibility and trigger Maillard reactions, while oxidation during storage can degrade unsaturated oils and form products associated with oxidative and inflammatory stress. Controlled fermentation or optimized extrusion may instead increase the release and bioaccessibility of bound polyphenols or alter microbial metabolites. Genotype-by-environment interactions also change functional-compound profiles, yet many studies provide insufficient information about cultivar and agronomic conditions. Human investigations differ in disease stage, metabolic status, habitual diet and intervention design, reducing reproducibility and generalizability.

Future work should test intact cereals and legumes under realistic dietary conditions rather than assume that a purified ingredient represents an entire food. Human interventions need clearly defined disease stages, standardized dietary backgrounds and sufficient duration, while stratification by insulin resistance, gut microbiota and habitual eating patterns could help explain different metabolic responses. Metabolomics, foodomics and microbiome analysis may reveal interactions concealed by supplement-based experiments. Crop-based blending also warrants systematic evaluation because cereals and legumes can contribute complementary fiber, phenolics, proteins and fatty acids, but existing combination studies use inconsistent crops, doses and experimental models. Longer-term safety, dose–response relationships and evidence-based intake ranges remain insufficiently characterized. The review therefore identifies cereal- and legume-based foods as promising complementary resources for NAFLD research, not as a proven preventive diet or a basis for clinical recommendation.

Subject of Research: Review of cereal and legume bioactive compounds in evidence concerning non-alcoholic fatty liver disease

Article Title: Compositional diversity and dietary implications of cereal and legume crops as functional resources for non-alcoholic fatty liver disease prevention: a review

Article References: Kim, H.-J., Han, N., & Lee, Y.-Y. (2026). Compositional diversity and dietary implications of cereal and legume crops as functional resources for non-alcoholic fatty liver disease prevention: a review. Food Science and Biotechnology. https://doi.org/10.1007/s10068-026-02346-y

Image Credits: AI Generated

DOI: 10.1007/s10068-026-02346-y

Keywords: non-alcoholic fatty liver disease, cereal crops, legume crops, branched-chain amino acids, dietary fiber, phenolic compounds, fatty acids, whole-food matrices, food processing, gut–liver axis, Compositional, diversity

MASLD, formerly known as non-alcoholic fatty liver disease, affects roughly a third of adults globally and begins silently as fat accumulates inside liver cells. If unchecked, the condition can progress to inflammation, fibrosis, and ultimately cirrhosis or liver cancer. Because the disease is driven by diet and metabolic imbalance rather than a single pathogen, prevention has become the central strategic goal. The Yanbian University group, led by corresponding authors Haidan Yuan and Guangchun Piao, argued that botanical resources with documented health benefits could serve as accessible prophylactic agents, and P. longifolia, a common edible vegetable in Inner Mongolia historically recognized in northeastern China for its health-promoting properties, was an obvious candidate to test.

The investigation began with a rigorous chemical census. Using ultra-high-performance liquid chromatography coupled to quadrupole-orbitrap mass spectrometry, or UHPLC-QE-MS, the researchers characterized 25 major bioactive constituents in the plant. This chemical blueprint served as the foundation for everything that followed. Each identified compound was then fed into a network pharmacology analysis, a computational strategy that maps interactions between bioactive molecules, their protein targets, and disease pathways. Rather than attributing an effect to one magic bullet, network pharmacology embraces the multi-component, multi-target logic that underlies most botanical interventions, and it allowed the team to predict which signaling hubs the plant’s constituents were most likely to engage.

To move from prediction to measurement, the researchers performed untargeted metabolomics on both serum and liver tissue from experimental animals. Metabolic profiling identified 18 differential metabolites in serum and 15 in liver tissue, a pattern that converged on two primary regulatory hubs: the AMPK axis and the NF-κB axis. AMPK, or AMP-activated protein kinase, functions as the cell’s energy sensor, switching on fat oxidation and shutting down lipogenesis when cellular energy status shifts. NF-κB, by contrast, is a transcription factor that orchestrates inflammatory responses, and its chronic activation in the liver is a hallmark of progression from simple steatosis to steatohepatitis. The metabolomics data suggested that P. longifolia was engaging both hubs simultaneously.

Experimental validation followed in vivo and in vitro. Animals given a high-fat diet developed obesity, hepatic steatosis, and early hepatic injury, the classic triad of emerging MASLD. When the diet was paired with GYC intervention, the researchers found that the plant effectively prevented high-fat diet-induced obesity, fat accumulation in the liver, and the earliest signs of hepatic damage. The findings, published on 15 October 2026 as an open-access article carrying the DOI 10.1038/s41538-026-01193-9, demonstrated that the intervention maintained lipid homeostasis and tempered early hepatic inflammatory responses by activating the AMPK signaling axis while suppressing the NF-κB and MAPK pathways.

The mechanistic picture that emerges is one of coordinated metabolic and inflammatory control. By activating AMPK, the plant’s constituents appear to restore the liver’s lipid-handling equilibrium, promoting fatty acid oxidation and limiting de novo lipogenesis, the process by which excess carbohydrate is converted into stored fat. By suppressing NF-κB and the MAPK cascade, another signaling family that propagates inflammatory signals, the intervention dampens the cytokine-driven inflammation that converts benign fat accumulation into active liver disease. Metabolomics confirmed that these pathway shifts were mirrored by measurable changes in circulating and hepatic metabolites, linking molecular signaling to the systemic metabolic state.

What makes the study technically notable is its integrated design. Chemical profiling supplied the compound inventory, network pharmacology predicted the target landscape, and metabolomics measured the actual metabolic consequences, with in vivo and in vitro experiments closing the loop. This triangulation reduces the risk that a single method’s artifacts drive the conclusion. The convergence of 18 serum and 15 liver differential metabolites on the AMPK and NF-κB axes, predicted independently by network pharmacology, provides a robust scientific rationale for utilizing GYC as a functional food resource or a promising prophylactic agent for MASLD prevention.

The work also carries cultural and agricultural weight. P. longifolia is not an exotic rainforest remedy but a vegetable already eaten regularly in Inner Mongolia, meaning the gap between laboratory finding and dietary practice is unusually narrow. The researchers, based in the College of Pharmacy at Yanbian University and the Key Laboratory of Natural Medicines of the Changbai Mountain under the Ministry of Education, framed the plant as a botanical resource historically recognized in northeastern China for its health-promoting benefits, and their data now give that recognition a molecular footing. The study was supported by the Jilin Province Science and Technology Development Plan Project and the National Natural Science Foundation of China.

For the global food science community, the findings arrive at a moment when MASLD prevention is urgently sought and dietary intervention remains the most practical lever. A vegetable that activates the liver’s energy sensor and quiets its inflammatory circuits, consumed as food rather than as a pill, represents a compelling model for functional food design. The Yanbian University team’s work suggests that the answer to a modern metabolic epidemic may have been growing on the Inner Mongolian plateau all along, waiting for metabolomics to reveal its mechanism.

Subject of Research: Preventive mechanisms of Potentilla longifolia against MASLD based on chemical profiling, network pharmacology, and metabolomics

Article Title: Preventive mechanisms of Potentilla longifolia against MASLD based on chemical profiling, network pharmacology, and metabolomics

Article References: Lin, S., Zhang, L., Wang, Z., Li, J., Cui, H., Bao, F., Di, Y., Xu, C., Dai, T., Yuan, H., & Piao, G. (2026). Preventive mechanisms of Potentilla longifolia against MASLD based on chemical profiling, network pharmacology, and metabolomics. npj Science of Food. https://doi.org/10.1038/s41538-026-01193-9

Image Credits: AI Generated

DOI: 10.1038/s41538-026-01193-9

Keywords: Preventive, mechanisms, Potentilla, longifolia, against, MASLD, based, chemical, profiling, network, pharmacology, metabolomics

The research, led by Junna Lu, Xiaochun Xie, and Chao Yang with corresponding authors He Shen, Fangman Chen, and Kam W. Leong, spans institutions in China and the United States, including the Institute of Biomedical Engineering of the Chinese Academy of Medical Sciences and Peking Union Medical College, South China University of Technology, and Columbia University. The team set out to solve a delivery problem that has dogged every hydrogen formulation to date. Hydrogen-rich water, the most common vehicle used in both experiments and consumer products, holds only a few parts per million of dissolved gas, and that gas begins diffusing out the moment the bottle is opened. Pills and capsules that generate hydrogen through chemical reactions tend to release it in an uncontrolled burst, much of it lost in the stomach before it ever reaches the intestine where many inflammatory diseases actually reside.

The researchers’ answer is a new class of materials they call gas-releasing frameworks, or GRFs. The name is a deliberate nod to metal-organic frameworks, the porous crystalline materials famous for storing gases at densities approaching their liquid state. GRFs apply that storage logic to a therapeutic gas, but with a twist: rather than merely adsorbing hydrogen into static pores, the framework is built from components that react dynamically to release the gas on cue. According to the study, the resulting material stores twenty thousand times more hydrogen than hydrogen-rich water of comparable volume. That figure is not a minor optimization; it is the difference between a formulation that is pharmacologically irrelevant and one that can plausibly deliver a therapeutic dose in a swallowable form.

Storage alone would be a modest achievement if the gas simply escaped at the first sign of acid. One of the central design challenges in gastrointestinal drug delivery is that the stomach is a chemically hostile environment, with a pH low enough to trigger premature reactions in many responsive materials. Conventional hydrogen-releasing formulations, the authors note, suffer burst leakage in acidic gastric fluid, dumping their payload where it is least useful. The GRFs were engineered to remain stable under those acidic conditions and instead release their hydrogen cargo in the intestine, where the pH rises and where inflamed tissue provides a distinct chemical microenvironment. The result is a formulation that behaves less like a leaky balloon and more like a targeted depot, sustaining release over time and preferentially at sites of inflammation.

The chemistry behind that selectivity is worth unpacking, because it illustrates how modern drug delivery increasingly borrows from materials science rather than classical pharmacology. A framework that stores hydrogen must contain reactive hydride-like components, and many of the most effective hydrogen-generating chemistries involve boron, an element with a complicated toxicological reputation. A naive design would simply dissolve or degrade, scattering boron-containing residues through the body. The GRF design instead anticipates its own afterlife. Once the hydrogen has been released, the framework reconstitutes itself into a silicon-oxygen-boron architecture that sequesters the toxic element within a stable solid matrix. The practical consequence, demonstrated in the study, is that boron is preferentially eliminated in the feces rather than absorbed into systemic circulation, a self-limiting safety feature built directly into the material’s degradation pathway.

That kind of end-to-end thinking, from payload to byproduct, is what separates this work from much of the hydrogen literature. The authors describe the frameworks as dynamic, meaning the material’s structure changes state as it performs its function: intact and hydrogen-loaded in the stomach, actively releasing gas in the inflamed intestine, and finally converting into a benign, excretable solid. Each transition is governed by the local chemical environment, so the same pill behaves differently depending on where it finds itself in the digestive tract. It is a level of environmental responsiveness that conventional hydrogen water or effervescent tablets cannot approach, and it addresses the tunability problem that the authors identify as a core weakness of prior formulations.

To test whether the delivery advantage translated into therapeutic benefit, the team turned to three established animal models of inflammatory disease. The first was colitis induced by dextran sulfate sodium, a widely used chemical model that damages the intestinal epithelium and recapitulates key features of inflammatory bowel disease. The second was radiation-induced colitis, a model relevant to the intestinal injury that patients undergoing pelvic or abdominal radiotherapy routinely suffer. The third was non-alcoholic fatty liver disease induced by a high-fat diet, extending the therapeutic question beyond the gut to the liver, an organ intimately connected to intestinal health through the portal circulation. In all three models, the GRF formulation outperformed hydrogen-rich water in mitigating oxidative damage and inflammation.

The consistency across those models matters. Oxidative stress and inflammation are intertwined processes: damaged tissue generates reactive oxygen species, which activate inflammatory signaling pathways, which recruit immune cells that generate still more reactive species. A therapy that interrupts this cycle at its source, by selectively neutralizing the most damaging oxidants, could in principle help across a spectrum of conditions rather than a single disease. The fact that a single delivery platform showed benefit in chemically induced colitis, radiation injury, and metabolic liver disease suggests that the limiting factor for hydrogen therapy has indeed been delivery rather than biology. When the gas actually arrives at the target tissue in sufficient quantity and lingers there, the preclinical promise reported across the hydrogen literature becomes reproducible.

None of this means hydrogen therapy is ready for the clinic, and the study’s authors are appropriately measured in their claims. The work was conducted in animal models, and the translation from mice to humans is littered with therapies that shone in colitis models but failed in patients with inflammatory bowel disease. Dosing is a particular unknown: the twenty-thousand-fold storage advantage is measured against hydrogen-rich water, but establishing a safe and effective human dose of a reactive gas-releasing solid will require its own body of pharmacology. The long-term fate of the reconstituted silicon-oxygen-boron framework, while demonstrably biased toward fecal elimination, will need to be characterized across repeated dosing and in diseased tissue environments that may alter degradation kinetics. The authors report no competing interests, and the work was funded by the National Natural Science Foundation of China and the CAMS Innovation Fund for Medical Sciences.

Still, the conceptual contribution is substantial and likely to ripple outward beyond hydrogen. Gasotransmitters, a class that includes nitric oxide, carbon monoxide, and hydrogen sulfide as well as hydrogen, are increasingly recognized as genuine signaling molecules with therapeutic potential, but all of them share the delivery problem that has frustrated hydrogen: they are volatile, poorly soluble, and hard to confine. A framework platform that stores a gas at high density, shields it from premature release, targets it to inflamed tissue, and then renders its own byproducts safely excretable is a template that could in principle be adapted to other therapeutic gases. The authors frame the GRFs as a feasible, safe, and translatable strategy for gastrointestinal delivery of therapeutic gases and for the treatment of inflammatory disorders, and on the evidence presented, that framing does not overreach. For a field that has struggled to separate credible science from hydrogen-water hype, the arrival of a rigorously engineered, peer-reviewed delivery platform may finally give molecular hydrogen the pharmacological credibility it has been missing.

Subject of Research: Gas-releasing framework materials for targeted gastrointestinal delivery of therapeutic molecular hydrogen to treat inflammatory diseases

Article Title: Gastrointestinal tract delivery of hydrogen by dynamic gas-releasing frameworks

Article References: Lu, J., Xie, X., Yang, C., Zhang, Y., Zhao, X., Lu, H., Sun, M., Chen, F., Wang, Y., Shao, D., Leong, K. W., & Shen, H. (2026). Gastrointestinal tract delivery of hydrogen by dynamic gas-releasing frameworks. Nature Communications. https://doi.org/10.1038/s41467-026-78290-6

Image Credits: AI Generated

DOI: 10.1038/s41467-026-78290-6

Keywords: molecular hydrogen, gasotransmitters, drug delivery, gas-releasing frameworks, colitis, inflammatory bowel disease, non-alcoholic fatty liver disease, oxidative stress, biomaterials, boron toxicity, gastrointestinal tract, Nature Communications

MASLD, the renamed and rigorously redefined successor to what was long called non-alcoholic fatty liver disease, affects a large share of adults globally and is tightly entwined with obesity, type 2 diabetes, and cardiovascular risk. Under the 2023 consensus framework from the major hepatology societies, patients with hepatic steatosis and at least one cardiometabolic risk factor are classified as MASLD, while those who also drink moderate amounts of alcohol fall into a new category called metabolic dysfunction and alcohol-associated liver disease, or MetALD. That distinction matters clinically, because MetALD carries a higher mortality risk and more severe hepatic outcomes than MASLD alone. With only one drug, resmetirom, approved for the inflammatory stage of the disease, prevention through lifestyle remains the cornerstone of care.

The research team drew on seven cycles of the National Health and Nutrition Examination Survey, or NHANES, collected between 2005 and 2018. From an initial pool of more than 70,000 participants, the investigators identified 3,048 adults with steatotic liver disease: 2,146 with MASLD and 902 with MetALD. Hepatic steatosis was assessed using the fatty liver index, a validated composite of body mass index, waist circumference, triglycerides, and gamma-glutamyltransferase, while metabolic criteria followed the latest international consensus definitions. Participants were then followed through the end of 2019, with deaths captured from national mortality records and classified by cause, including cardiovascular disease, malignancy, diabetes, and respiratory illness.

To characterize diet, the researchers used three complementary tools. The Dietary Inflammatory Index, or DII, scores the overall inflammatory potential of a person’s intake across dozens of food components, with higher values signaling a more pro-inflammatory pattern. The Composite Dietary Antioxidant Index, or CDAI, aggregates intake of six key antioxidants: vitamins A, C, and E, zinc, selenium, and carotenoids. The Dietary Antioxidant Quality Score, or DAQS, measures how closely a person’s antioxidant intake approaches recommended daily levels, ranging from zero for poor quality to six for high quality. All three metrics were calculated from two 24-hour dietary recall interviews, one conducted in person and a second by telephone days later.

The results were striking. Across the entire cohort, adults in the highest tertile of DII had roughly double the all-cause mortality risk of those in the lowest tertile after full adjustment for age, sex, income, body mass index, smoking, sedentary time, energy intake, supplement use, cancer, diabetes, liver enzymes, uric acid, and hyperlipidemia. Conversely, those in the highest tertile of CDAI had about 56 percent lower mortality risk, and those with the highest DAQS had roughly 43 percent lower risk. In the MASLD subgroup alone, the pattern held: the most pro-inflammatory diets nearly doubled mortality risk, while the highest antioxidant capacity and quality were each associated with about half the risk of death.

The MetALD subgroup told a more dramatic, if statistically delicate, story. Among these moderate drinkers, a pro-inflammatory diet was associated with nearly four times the all-cause mortality risk compared with the least inflammatory diets, the strongest association observed anywhere in the study. The protective trends for antioxidant capacity and quality pointed in the same favorable direction but did not reach conventional statistical significance, likely because only 58 deaths occurred in this smaller subgroup, limiting statistical power. When the researchers jointly analyzed diet and disease subtype, using MASLD patients with the worst diets as the reference, MetALD patients with the highest antioxidant quality scores showed an 81 percent lower all-cause mortality risk, and MASLD patients with top-quality antioxidant diets showed a 62 percent reduction.

Cardiovascular mortality, a leading killer in this population, followed a similar trajectory. Dietary antioxidant quality showed a consistent protective association in the total cohort and among MASLD patients, where the highest DAQS group had about 58 percent lower cardiovascular death risk. In the joint analysis, the apparent benefits were even larger among MetALD patients, with the highest antioxidant quality and capacity tertiles associated with risk reductions exceeding 80 percent, though wide confidence intervals counseled caution. Restricted cubic spline analyses reinforced the overall picture, revealing largely monotonic relationships in which mortality risk climbed with increasing dietary inflammatory potential and fell with rising antioxidant exposure.

Seeking mechanism, the team ran exploratory mediation analyses using inflammatory and hematological markers, including the neutrophil-to-lymphocyte ratio, platelet counts, and the platelet-to-HDL cholesterol ratio. Among MASLD patients, indirect pathways through platelets and the platelet-to-HDL ratio were statistically significant, but the effects operated in opposing directions to the direct effects, a pattern the authors describe as inconsistent mediation or suppression rather than clean biological mediation. In plain terms, diet quality clearly tracks with systemic inflammatory and blood markers, but those markers do not act as simple pipelines between diet and death. In the MetALD subgroup, no significant mediation emerged at all, hinting that alcohol-related biological alterations, gut microbiome changes, and hepatocellular protection may weave a more tangled web in moderate drinkers.

Subgroup analyses added nuance about who benefits most. The associations between diet and mortality were modified by age, sex, smoking status, body mass index, cancer, diabetes, and crucially, liver fibrosis stage as measured by the FIB-4 index. When fibrosis was minimal, with FIB-4 below 1.3, the dietary associations were strongest; as fibrosis advanced, the protective effects of antioxidant diets weakened and the inflammatory diet signal lost significance. This suggests that dietary intervention may deliver its greatest survival payoff early in the disease course, before irreversible scarring takes hold, a window when patients and clinicians still have real leverage.

The authors are candid about limitations. NHANES relies on self-reported diet and behavior, inviting recall bias; the 24-hour recalls cannot fully capture long-term eating patterns or precise alcohol intake; some plant-derived antioxidant compounds could not be included in the indices; and the modified application of the 2023 diagnostic criteria, including the omission of Asian-specific body mass cutoffs, may affect generalizability. The small number of deaths among MetALD participants in particular warrants replication in larger cohorts. Still, the practical implications are hard to ignore. For the many patients who cannot achieve complete abstinence, the study suggests that swapping refined grains for whole grains, avoiding fried foods and processed red meat, and loading the plate with fiber-rich vegetables, legumes, and dark-colored fruits such as anthocyanin-packed berries could meaningfully blunt mortality risk. Optimizing the anti-inflammatory and antioxidant quality of the diet, the authors conclude, should stand alongside alcohol restriction as a central nutritional strategy for improving prognosis across the entire steatotic liver disease spectrum.

Subject of Research: Associations of dietary inflammatory and antioxidant indices with mortality risk in MASLD and MetALD

Article Title: Differential Associations of Dietary Inflammatory Index and Dietary Antioxidant Indices With Mortality Risk From MASLD/MetALD: Results From a Large Population‐Based Study

Article References: Lyu, H., Chen, H., Zhan, Z., Qin, Y., Mao, L., Guo, M., Mo, Y., & Shen, T. (2026). Differential Associations of Dietary Inflammatory Index and Dietary Antioxidant Indices With Mortality Risk From MASLD / MetALD : Results From a Large Population‐Based Study. Food Science & Nutrition, 14(10), Article e72429. https://doi.org/10.1002/fsn3.72429

Image Credits: AI Generated

DOI: 10.1002/fsn3.72429

Keywords: MASLD, MetALD, fatty liver disease, Dietary Inflammatory Index, Composite Dietary Antioxidant Index, Dietary Antioxidant Quality Score, NHANES, mortality, nutrition, oxidative stress, cardiovascular mortality, liver fibrosis

The research team, led by Hongxia Liu and Yan Wang of the Department of Pediatrics at Henan Provincial People’s Hospital, affiliated with People’s Hospital of Zhengzhou University, set out to address a persistent gap in the literature. Socioeconomic shifts in China have clearly driven an increase in metabolic disorders, but long-term trend data specifically covering youth aged 5 to 24 have remained scarce. Most existing studies focus either on adults or on very young children, leaving adolescents and young adults in a statistical blind spot even though habits formed in these years often persist for life. By analyzing the full 1990 to 2021 period, the researchers could capture the entire arc of China’s extraordinary development, from the early years of market reform through urbanization, dietary change, and the digital era.

At the heart of the study is a metric called the disability-adjusted life year, or DALY, which combines years of life lost to premature death with years lived in disability or ill health. One DALY represents one lost healthy year. By calculating age-standardized DALY rates, abbreviated ASDR, the investigators could compare disease burden across years and populations while accounting for shifts in the age structure of the population. The team focused on four conditions: hypertension, non-alcoholic fatty liver disease, obesity, and type 2 diabetes mellitus. Each of these was once considered an affliction of middle age, yet all four now appear, with varying frequency, among people in their teens and twenties.

The analytical toolkit was considerable. To detect changes in trajectory rather than assuming smooth linear trends, the researchers used Joinpoint regression, a statistical technique originally developed for cancer surveillance that identifies the years at which a trend’s direction or steepness shifts significantly. From these turning points they calculated average annual percentage changes, or AAPCs, which quantify how fast the burden rose or fell. To look forward, they applied a Bayesian age-period cohort model, a probabilistic framework that disentangles the effects of age, calendar time, and birth cohort on disease rates and uses that structure to generate forecasts. Finally, a decomposition analysis partitioned the observed changes in DALYs into three contributing forces: changes in disease rates themselves, population growth, and population aging.

The results tell a story of divergence. Hypertension showed the most encouraging trajectory, with its age-standardized DALY rate falling at an average annual rate of 2.89 percent, a decline that outpaced the global average for the same age group. This improvement, the authors suggest, reflects decades of public health investment, including national salt-reduction awareness efforts and the screening programs embedded in school health services. Yet even this success is incomplete, because hypertension in youth often goes undetected and untreated, silently seeding cardiovascular risk for later life.

Obesity and type 2 diabetes moved in the opposite direction. The age-standardized DALY rate for obesity climbed at an average annual rate of 3.06 percent, while the rate for type 2 diabetes rose at 3.12 percent, both consistent with the upward trends observed globally. These figures align with a broader body of evidence documenting the rapid rise of childhood overweight and obesity in China, driven by increased consumption of sugar-sweetened beverages, ultra-processed foods, and energy-dense diets, alongside a documented decline in physical activity and a surge in sedentary screen time among children and adolescents. The link between early obesity and early-onset type 2 diabetes is well established: excess adiposity in childhood promotes insulin resistance, and the pancreatic beta cells, stressed for years, begin to fail decades earlier than in previous generations. A condition that was once almost unheard of in teenagers is now a recognized pediatric diagnosis in China, prompting the Chinese Medical Association to issue dedicated consensus guidance on managing type 2 diabetes in children and adolescents.

Non-alcoholic fatty liver disease, a condition in which fat accumulates in the liver of someone who drinks little or no alcohol, presented the most nuanced pattern. Across the full 32-year window, its DALY rate declined at an average annual rate of 1.84 percent. But the Joinpoint analysis revealed that this decline was not uniform: after the mid-2010s, the burden rebounded, and the resurgence was particularly pronounced among females. This reversal matters because hepatic steatosis in childhood is increasingly recognized as a marker of broader metabolic risk, and fatty liver disease in the presence of insulin resistance can progress toward inflammation, fibrosis, and, in the long term, cirrhosis and liver cancer. The authors emphasize that this recent resurgence among young women demands targeted attention, and they note that awareness of the condition remains low even among young adults, a gap that randomized intervention trials in China have attempted to close through education campaigns aimed at prevention.

Sex differences emerged as a consistent theme throughout the analysis. Males bore a higher proportion of DALYs across the metabolic conditions studied, a pattern that echoes physiological and behavioral research on why men accumulate more abdominal visceral fat, the metabolically active depot most strongly linked to insulin resistance and cardiovascular risk. Behavioral factors compound the biology: smoking initiation in adolescence remains common among Chinese males, and smoking interacts with metabolic disease in ways that accelerate vascular damage. At the same time, the female-specific rebound in fatty liver disease highlights that risk is not distributed simply, and the authors argue explicitly for sex-specific public health strategies rather than one-size-fits-all interventions.

The decomposition analysis added a crucial interpretive layer. It showed that the increases in DALYs were driven primarily by epidemiological change, meaning shifts in the underlying rates of disease themselves, rather than by demographic forces. Population growth and population aging actually exerted mitigating effects on the age-standardized burden, underscoring that the worsening picture is not an artifact of there simply being more young people. The diseases themselves are becoming more common relative to population size, which makes the trend harder to dismiss and more consequential for health planning.

Looking ahead, the Bayesian projections to 2030 extend the bifurcation into the coming decade. Hypertension is forecast to continue improving, but obesity and type 2 diabetes are predicted to worsen, placing an expanding burden on young people precisely at the ages when they enter the workforce and begin families. The findings arrive as China pursues national frameworks including the Outline for Building a Healthy China 2030, the National Nutrition Plan, and dedicated policies on weight control among children and adolescents and on strengthening school physical education. The study’s message to policymakers is that these frameworks must be sharpened and targeted: the hypertension gains show that sustained intervention works, while the relentless rise of obesity and diabetes shows where the next battle lies. Without urgent, sex-aware, and age-tailored action, a generation of young Chinese faces a future in which the chronic diseases of adulthood arrive decades early.

Subject of Research: Long-term trends in the burden of hypertension, obesity, type 2 diabetes, and fatty liver disease among Chinese youth aged 5 to 24 from 1990 to 2021

Article Title: The burden of metabolic diseases in Chinese youth, 1990–2021: a Global Burden of Disease Study 2021

Article References: Liu, H., Zhang, B., Ma, C., Sun, X., Gao, L., & Wang, Y. (2026). The burden of metabolic diseases in Chinese youth, 1990–2021: a Global Burden of Disease Study 2021. Pediatric Research. https://doi.org/10.1038/s41390-026-05311-x

Image Credits: AI Generated

DOI: 10.1038/s41390-026-05311-x

Keywords: Global Burden of Disease, Chinese youth, obesity, type 2 diabetes, hypertension, non-alcoholic fatty liver disease, DALY, pediatric metabolic health, sex disparities, Bayesian projection, public health, epidemiology

The breadth of melatonin’s reported activities is striking. Beyond its sedative effect, the review catalogs antitumor, immunomodulatory, antioxidant, antihypertensive and cardioprotective actions, along with roles in regulating body weight, gastrointestinal function, reproduction and thermoregulation. Part of this versatility is chemical: melatonin crosses biological membranes freely and reaches nearly every compartment of the cell. Part of it is signaling: melatonin binds specific G-protein-coupled receptors, but it also engages intracellular pathways that govern whether a cell survives stress, divides, inflames or dies. The question the review tackles is which of these pathways best explains the hormone’s pharmacological reach, and its answer centers on SIRT1, the most intensively studied member of the mammalian sirtuin family.

SIRT1 is a nicotinamide adenine dinucleotide, or NAD+, dependent deacetylase, meaning it removes acetyl chemical groups from proteins only when the metabolic cofactor NAD+ is available. This makes the enzyme a direct sensor of cellular energy status, because NAD+ levels rise and fall with nutrient availability, fasting and metabolic strain. SIRT1 shuttles between the cytoplasm and the nucleus, where it strips acetyl groups from histones, the spools around which DNA is wound, and from a growing list of non-histone proteins including the tumor suppressor p53, the transcription factors FoxO and NF-κB, and the mitochondrial regulator PGC-1α. Through these targets, SIRT1 influences cell survival, metabolism, growth, aging and resistance to stress, which is precisely the portfolio of processes that goes wrong in chronic disease.

The review’s central claim is that melatonin can modulate SIRT1 activity, and that this modulation in turn shapes four fundamental cellular responses: inflammation, oxidative stress, apoptosis and autophagy. In inflammatory bowel disease, for example, recent work cited in the review shows that melatonin restores the intestinal mucosal barrier by activating a SIRT1-LKB1-pAMPK signaling axis. In autoimmune and sepsis models, SIRT1 deacetylates components of the NF-κB pathway and the NLRP3 inflammasome, damping the production of tumor necrosis factor alpha, interleukin-1 and other inflammatory mediators. Because NF-κB sits upstream of cyclooxygenase-2 and inducible nitric oxide synthase, a single deacetylation event can cascade into a broad suppression of the inflammatory program.

The cardiovascular evidence is among the most developed. In type 2 diabetic rats, reduced SIRT1 signaling worsens myocardial ischemia-reperfusion injury, and melatonin treatment restores protection through the enzyme. Melatonin receptor-mediated cardioprotection against ischemia-reperfusion has likewise been traced to SIRT1. In diabetic hearts, melatonin prevents Drp1-mediated mitochondrial fission, the excessive fragmentation of mitochondria that starves cardiomyocytes of energy, via the SIRT1-PGC-1α pathway, and activation of the SIRT1-PGC-1α-SIRT3 cascade protects against mitochondrial dysfunction in isoproterenol-induced myocardial injury. The chemotherapy drug doxorubicin, notorious for causing heart damage, appears less toxic when melatonin activates the Sirt1/Nrf2 pathway, inhibiting oxidative stress, pyroptosis and apoptosis. In sepsis-induced cardiac dysfunction, melatonin acts through SIRT1 to regulate both apoptosis and autophagy, including SIRT1-mediated deacetylation of beclin-1 and of the transcription factor TFEB, which orchestrates lysosomal clearance of damaged material.

The kidney tells a parallel story. Melatonin attenuates acute kidney ischemia-reperfusion injury in diabetic rats by activating the SIRT1/Nrf2/HO-1 axis, a canonical antioxidant pathway in which Nrf2, once deacetylated and stabilized, switches on heme oxygenase-1 and other detoxifying genes. In diabetic kidney disease, protection runs through SIRT1/NLRP3 signaling, curbing the inflammasome-driven inflammation that scars the filtering units of the kidney. Melatonin also prevents acute kidney injury in severely burned rats via SIRT1 activation, and in cadmium-induced proximal tubular injury it preserves mitochondrial function by blocking fission through SIRT1-PGC-1α. Perhaps most intriguingly, melatonin lowers the abundance of hypoxia-inducible factor 1α in human proximal tubular cells by preventing its deacetylation by sirtuin 1, a reminder that SIRT1’s effects are not uniformly protective but context-dependent, and that melatonin’s modulation of the enzyme can push it in either direction depending on the tissue and insult.

In the liver, the review highlights melatonin’s effects on non-alcoholic fatty liver disease, a condition now affecting a substantial share of the world’s overweight and obese population. Melatonin’s benefits in fatty liver models are linked to the microRNA-34a-5p/Sirt1 axis and to autophagy, the cellular recycling system that clears lipid droplets and damaged organelles. In hypercholesterolemic mice, melatonin’s modulation of sirtuin-1 attenuates liver injury. The enzyme also mediates protection against toxic exposures: melatonin inhibits benzo(a)pyrene-induced apoptosis in mouse liver through the miR-34a/Sirt1/autophagy pathway, and it attenuates arsenic-induced liver injury through Nrf2/HO-1, apoptosis and miR-34a/Sirt1/autophagy routes. In alcoholic liver injury, melatonin-induced SIRT1 disrupts the cereblon-YY1-CYP2E1 signaling pathway, reducing the oxidative metabolism of alcohol that generates damaging free radicals, while in sepsis-induced liver injury melatonin activates SIRT1/STAT3 signaling to rescue dysregulated gluconeogenesis.

The reproductive findings may prove the most clinically provocative. In polycystic ovary syndrome, melatonin enhances SIRT1 expression in granulosa cells to ameliorate excessive PINK1/Parkin-mediated mitophagy and to protect mitochondrial membranes through PDK1/Akt signaling, and it attenuates Drp1-driven mitochondrial fission through SIRT1 upregulation. The ROS/SIRT1/STAR axis has been identified as a target through which melatonin corrects atrazine-induced mitochondrial dysfunction and steroid disorders in granulosa cells. In oocytes, melatonin protects against chronic stress-induced meiotic defects by regulating SIRT1, and follicular fluid insufficiency of melatonin has been proposed as a reversible cause of the chromosomal abnormalities seen in oocytes of advanced maternal age. On the male side, melatonin protects mouse testes from palmitic acid-induced lipotoxicity in a SIRT1-dependent manner, ameliorates diabetic impairment of Leydig cell steroidogenic function through SIRT1 activation, and modulates SIRT1 to counter LPS-induced testicular nitro-oxidative stress and inflammation. Human trials add a translational note: melatonin supplementation improved semen parameters in men with idiopathic infertility in a triple-blind randomized placebo-controlled trial, and melatonin therapy added benefit to varicocelectomy in a double-blind trial, with epigenetic effects in a varicocele rat model mediated by silent information regulator 1.

The musculoskeletal section rounds out the picture. In osteoarthritis, melatonin exerts cytoprotective and anti-inflammatory effects in human chondrocyte cells and in rabbit models via the SIRT1 pathway, prevents cartilage matrix degradation by inhibiting NF-κB through SIRT1, and regulates chondrocyte hypertrophy and apoptosis through the Sirt1/P53/P21 axis. It also promotes sirtuin 1 expression to inhibit the IRE1α-XBP1S-CHOP branch of the unfolded protein response, reducing endoplasmic reticulum stress-mediated apoptosis in chondrocytes. In intervertebral disc degeneration, melatonin protects vertebral endplate chondrocytes against apoptosis and calcification via the Sirt1-autophagy pathway and holds promise through inhibiting M1-type macrophage polarization via SIRT1/Notch signaling. Even in cancer the relationship is bidirectional: whereas SIRT1 activation generally protects healthy tissue, melatonin’s antitumor activity in human osteosarcoma cells has been attributed to SIRT1 inhibition, underscoring that the same enzyme can be friend or foe depending on cellular context.

The authors are careful to note the limits of the evidence. Despite the breadth of preclinical data, they write that evidence regarding the role of SIRT1 in melatonin’s effects remains limited, and much of what is known comes from cell cultures and animal models rather than definitive human trials. Whether melatonin reliably activates SIRT1 in human tissues at supplement doses, and whether SIRT1 is necessary rather than merely correlated with the hormone’s benefits, will require pharmacological inhibitors, genetic models and properly powered clinical studies. Still, the synthesis is compelling in its coherence: a hormone produced by a tiny gland in the brain, acting through an NAD+-dependent enzyme that links metabolism to gene expression, appears to coordinate protective programs across organs as different as the heart, kidney, liver, ovary and joint. If future work confirms SIRT1 as the common mediator, melatonin’s humble reputation as a sleep aid may give way to something far more interesting, a cheap and safely tolerated molecule that tunes the body’s central longevity machinery.

Subject of Research: The role of the SIRT1 signaling pathway in the therapeutic effects of melatonin across disease models

Article Title: The therapeutic potential of melatonin: Focus on the SIRT1 signaling pathway

Article References: Vahidinia, Z., Behdarvandy, M., Azami Tameh, A., Barati, S., & Yasamian, A. (2026). The therapeutic potential of melatonin: Focus on the SIRT1 signaling pathway. Molecular Biology Reports, 53(1), Article 1667. https://doi.org/10.1007/s11033-026-12815-6

Image Credits: AI Generated

DOI: 10.1007/s11033-026-12815-6

Keywords: melatonin, SIRT1, sirtuins, NAD+, deacetylation, oxidative stress, autophagy, apoptosis, cardioprotection, diabetic cardiomyopathy, non-alcoholic fatty liver disease, polycystic ovary syndrome

The study, published in Food Science of Animal Resources, used a whey-derived milk polar lipid concentrate containing at least 25 percent total phospholipids, including sphingomyelin, phosphatidylcholine, phosphatidylethanolamine, and phosphatidylserine. Male C57BL/6J mice, a standard strain in metabolic research, were divided into four groups of six animals each. One group received a standard control diet, a second received a high-fat high-sucrose diet deriving 43 percent of its calories from fat and 24 percent from sucrose, a third received that same obesogenic diet modified so that milk fat was replaced with 8 percent of the milk polar lipid concentrate, and a fourth received the obesogenic diet supplemented with 0.01 percent orlistat, the pancreatic lipase inhibitor sold commercially as Xenical, serving as a positive control. The animals were followed for twelve weeks, with body weight and food intake recorded weekly and body composition assessed by dual-energy X-ray absorptiometry shortly before the study’s end.

The results were striking. Mice on the high-fat high-sucrose diet gained substantially more weight than controls, but the animals receiving milk polar lipids ended the study at a final body weight statistically indistinguishable from the normal-diet group. Fat mass, measured by DEXA scanning, was significantly lower in the supplemented animals, and the treatment partially restored lean mass while also improving bone mineral content, an intriguing secondary observation that suggests the lipids may help preserve skeletal status under metabolic stress. Food and calorie intake rose gradually in the unsupplemented high-fat group, but the researchers attributed this to increasing body mass rather than heightened appetite, noting that intake did not differ across groups during the early weeks when body weights were still comparable.

Blood chemistry told a similar story of protection. The obesogenic diet drove up total cholesterol and low-density lipoprotein cholesterol, both well-established indicators of dysregulated lipid metabolism, and elevated alanine aminotransferase and aspartate aminotransferase, the two enzymes clinicians rely on most heavily to detect liver cell damage. Supplementation with the milk lipid concentrate pushed all of these markers back toward normal levels. Serum triglycerides, curiously, were actually higher in the supplemented group than in the unsupplemented high-fat group, but the authors interpret this not as a metabolic failure but as a sign of enhanced lipid mobilization and export from liver and fat stores into circulation, consistent with prior evidence that dietary phospholipids influence very-low-density lipoprotein assembly and hepatic lipid handling. They caution that the relatively short four-hour fast before tissue collection may have introduced postprandial effects and call for future studies measuring free fatty acids and hepatic VLDL secretion rates to clarify the point.

Under the microscope, the differences were unmistakable. Adipocytes in the high-fat group were markedly enlarged, a hallmark of adipose tissue dysfunction that fuels chronic low-grade inflammation and floods peripheral organs with excess free fatty acids. Both the milk lipid and orlistat groups showed significantly smaller adipocytes and reduced weights of inguinal and mesenteric white adipose tissue depots. In the liver itself, hematoxylin and eosin staining and Oil Red O staining revealed heavy fat infiltration in the high-fat group, while the supplemented animals showed dramatically reduced steatosis, lower liver weights, and significantly reduced hepatic triglyceride content. Earlier work had suggested that milk phospholipids partly work by interfering with micellar lipid solubilization in the intestine, reducing absorption and increasing fecal lipid excretion, but the tiny amounts of intact phospholipids recovered in feces in prior studies indicated the supplements themselves are efficiently absorbed, hinting that they must also act systemically after uptake.

That systemic action is where the new study makes its most technically interesting contribution. The researchers probed the hepatic Wnt/β-catenin pathway, an evolutionarily ancient signaling cascade best known for orchestrating embryonic development but increasingly recognized as a metabolic regulator. The obesogenic diet significantly suppressed key components of the pathway, reducing hepatic expression of the co-receptor LRP6 and the ligand Wnt3a. Supplementation with the milk lipids, and to a comparable degree orlistat, restored LRP6 and Wnt3a expression, but only the milk lipid diet significantly upregulated total β-catenin, the pathway’s central transcriptional effector. When Wnt signaling is active, stabilized β-catenin enters the nucleus and suppresses adipogenic transcriptional programs driven by PPARγ and C/EBPα, thereby limiting lipid storage. Consistent with that model, the supplemented animals showed significantly reduced expression of PPARγ and its downstream partners DGAT1 and PLIN2, which govern triglyceride synthesis and lipid droplet formation, along with reduced SREBP1 and the de novo lipogenesis enzymes ACC, SCD1, and FAS.

The authors propose a plausible biophysical explanation for how dietary lipids could touch this membrane-anchored pathway. Polar lipids can alter the composition of cellular membranes, and membrane phosphoinositide metabolism is known to be essential for LRP6 activation, with prior work showing that Wnt3a-mediated formation of phosphatidylinositol 4,5-bisphosphate regulates LRP6 phosphorylation. Milk fat globule membrane supplementation has also been shown in lipidomic studies to enrich membranes in phosphatidylcholine and phosphatidylethanolamine. In other words, the phospholipids consumed in the diet may be incorporated into hepatic membranes in ways that sensitize the Wnt machinery, though the authors are careful to frame this as a plausible mechanism rather than a demonstrated one. Notably, milk-derived sphingomyelin has previously outperformed egg-derived sphingomyelin against hepatic steatosis, suggesting that the source and molecular composition of dietary lipids matter in ways the field is only beginning to map.

The second arm of the mechanism involves the gut microbiome, and here the study employed 16S rRNA gene sequencing of cecal contents processed through the DADA2 and QIIME pipelines. The obesogenic diet significantly reduced microbial alpha diversity, as measured by the Shannon index and phylogenetic diversity, and shifted the community structure into a cluster clearly separated from controls. The milk lipid group formed its own distinct cluster, separate from both the high-fat and orlistat groups, with PERMANOVA confirming significant separation between the supplemented and unsupplemented high-fat animals. Because the orlistat group’s microbiome remained similar to the high-fat group’s, the authors infer that the lipids’ microbial effects extend beyond simple inhibition of fat absorption. At the phylum level, supplementation partially reversed the diet-driven rise in Bacillota and boosted Verrucomicrobiota, the phylum housing Akkermansia muciniphila, a mucin-degrading bacterium celebrated for its associations with gut barrier integrity and metabolic health, and consistently depleted in patients with fatty liver disease and obesity.

Additional taxa shifts reinforced the picture. The high-fat diet enriched bile acid-resistant Lactobacillus and Limosilactobacillus species, a pattern previously linked to altered intestinal bile acid composition in fatty liver models, while the milk lipid diet selectively increased Akkermansia along with Romboutsia and members of the Christensenellaceae family, taxa reported to improve lipid metabolism partly through enhanced short-chain fatty acid production. Prior studies have shown that A. muciniphila supplementation attenuates hepatic steatosis and inflammation, modulates bile acid metabolism through the intestinal FXR-FGF15 axis, and enhances mitochondrial fatty acid oxidation via L-aspartate signaling along the gut-liver axis. The authors are appropriately measured about causality, emphasizing that their microbial findings show association rather than proof and that future work measuring microbial metabolites such as short-chain fatty acids and bile acids will be needed to close the loop.

Taken together, the study sketches a coordinated mechanism in which a single dietary component acts simultaneously on intracellular lipogenic signaling and on the ecology of the gut, offering a template for how food-derived bioactives might be engineered into functional ingredients for metabolic disease. The caveats are real: the work was conducted in mice, the intervention used a concentrated extract at a dose that would be difficult to translate directly to human diets, and the mechanistic links remain partly inferential. But with fatty liver disease affecting hundreds of millions of people and no approved pharmacological therapy for its early stages, the idea that the humble membrane lipids enveloping fat droplets in milk could simultaneously quiet a liver’s fat-building program and cultivate a healthier gut community is precisely the kind of convergent finding that could shape the next generation of nutritional interventions.

Subject of Research: Effects of dietary milk polar lipids on hepatic lipid accumulation, Wnt-PPARγ signaling, and gut microbiota in a mouse model of non-alcoholic fatty liver disease

Article Title: Dietary milk polar lipids ameliorate hepatic lipid accumulation through coordinated regulation of Wnt-PPARγ signaling and remodeling of the gut microbiota

Article References: Kim, H., Park, D., Kwon, Y.-J., & Imm, J.-Y. (2026). Dietary milk polar lipids ameliorate hepatic lipid accumulation through coordinated regulation of Wnt-PPARγ signaling and remodeling of the gut microbiota. Food Science of Animal Resources, 46(1), Article 83. https://doi.org/10.1007/s44463-026-00100-w

Image Credits: AI Generated

DOI: 10.1007/s44463-026-00100-w

Keywords: milk polar lipids, non-alcoholic fatty liver disease, Wnt/beta-catenin signaling, PPARgamma, gut microbiota, Akkermansia muciniphila, sphingomyelin, hepatic steatosis, short-chain fatty acids, gut-liver axis, high-fat high-sucrose diet, milk fat globule membrane

MASLD, previously known as non-alcoholic fatty liver disease, has become the most prevalent chronic liver condition globally, with an estimated worldwide prevalence of approximately 38 percent based on recent systematic reviews. It ranges from simple fat accumulation to inflammation and fibrosis and can progress to cirrhosis and hepatocellular carcinoma. There are few approved pharmacological treatments, and understanding the underlying molecular drivers is a priority for researchers. Mitochondrial dysfunction has long been recognized as a central feature of MASLD. Mitochondria are the energy factories of the hepatocyte, and when they fail, fatty acids accumulate inside the cell and inflammatory damage follows. Mitophagy — the selective autophagic degradation of damaged mitochondria — is the cell’s quality control system for keeping its mitochondrial network healthy. Earlier work from other groups has shown that restoring mitophagy, for instance with quercetin or cyanidin-3-O-glucoside, can improve fatty liver disease in animal models, and that impaired mitophagy is a mechanistic biomarker in patients with the disease. But the regulatory circuits that shut mitophagy down during MASLD development have remained incompletely mapped.

The new study, led by Mei Long of the Department of Rheumatology and Immunology at the First Affiliated Hospital of Hengyang Medical School, University of South China, together with Kewei Tan of the No. 922 Hospital of the People’s Liberation Army Joint Logistics Support Force and Yujie Dong of the Department of Ultrasound Medicine at the same institution, set out to fill that gap. The researchers first profiled ZNF143, a zinc finger transcription factor that binds specific GC-rich DNA motifs and acts both as an activator and repressor of transcription. ZNF143 is best studied in cancer biology, where it promotes glioma growth through KPNA2-mediated Hippo signalling and supports breast cancer cell survival through the NQO1–p53–Beclin1 axis under metabolic stress. Prior work by the same team had already implicated ZNF143 in fatty liver disease, showing that it inhibits hepatocyte mitophagy by upregulating the long non-coding RNA NEAT1 and activating the ROCK2 pathway. The current study extends that work by identifying an entirely separate, protein-level arm of the same transcription factor’s suppressive effect on mitochondrial quality control.

To test their hypothesis, the researchers used two complementary models of MASLD. The first was an in vivo model in which C57BL/6J mice were fed a high-fat diet for 16 weeks to induce hepatic steatosis and metabolic stress. The second was an in vitro model in which Huh-7 human hepatoma cells, a standard hepatic cell line, were exposed to free fatty acids to mimic lipid overload. Histological changes were assessed by hematoxylin and eosin staining, lipid accumulation was quantified by Oil Red O staining, and mitochondrial damage was assessed with JC-1 staining to monitor mitochondrial membrane potential and transmission electron microscopy to visualize mitochondrial ultrastructure. Serum and tissue markers of liver injury, including alanine aminotransferase, aspartate aminotransferase, total cholesterol and triglycerides, were measured to gauge the severity of hepatic dysfunction.

When the team examined the high-fat-diet-fed mice and the free-fatty-acid-treated Huh-7 cells, they found that ZNF143 was significantly upregulated in both settings, consistent with a role for this transcription factor in disease progression rather than simply a bystander effect. When the researchers knocked down ZNF143 using RNA interference, the consequences were striking: lipid accumulation in the liver decreased, mitochondrial damage was reduced, and liver injury markers fell. The mechanism behind this improvement was traced to a restoration of hepatocyte mitophagy, confirming that ZNF143 acts as a brake on mitochondrial quality control during MASLD.

The next step was to identify the transcriptional target through which ZNF143 exerts its effect. Using chromatin immunoprecipitation, the researchers demonstrated that ZNF143 binds directly to the promoter region of SMURF1, a HECT-type E3 ubiquitin ligase known for its role in ubiquitinating and degrading diverse substrate proteins in cancer, vascular remodeling and inflammatory signalling. Dual-luciferase reporter assays confirmed that this binding functionally activates SMURF1 transcription. In other words, ZNF143 does not merely correlate with MASLD; it actively turns up the expression of a ubiquitin ligase that then acts downstream.

SMURF1 has a complicated history in liver biology. Previous studies have shown that deleting Smurf1 attenuates liver steatosis in mice by stabilizing p53, and that Smurf1 aggravates fatty liver disease by stabilizing SREBP-1c, a master regulator of lipid synthesis, in an E3-activity-independent manner. Conversely, another study reported that SMAD-specific E3 ubiquitin protein ligase 1 can be protective in alcoholic steatohepatitis. The current study adds a new substrate to SMURF1’s growing portfolio in hepatic disease and clarifies how this E3 ligase suppresses mitochondrial quality control. Using co-immunoprecipitation, the team showed that SMURF1 physically interacts with TRPV1, the transient receptor potential vanilloid type 1 ion channel, and that SMURF1 ubiquitinates TRPV1, leading to its proteasomal degradation. TRPV1, the receptor activated by capsaicin, the pungent compound in chili peppers, has long been linked to metabolic health. Activation of TRPV1 by dietary capsaicin improves visceral fat remodelling through calcium influx, and TRPV1 activation prevents fatty liver disease in mice through upregulation of the mitochondrial uncoupling protein UCP2. By degrading TRPV1, SMURF1 removes a protective channel that supports mitochondrial and metabolic homeostasis in the hepatocyte.

The researchers then performed epistasis experiments to confirm the hierarchy of the pathway. When they knocked down TRPV1 in free-fatty-acid-treated Huh-7 cells that had already had ZNF143 depleted, the beneficial effect of ZNF143 knockdown on mitophagy was reversed. Similarly, overexpressing SMURF1 in ZNF143-depleted cells abolished the improvement in mitochondrial clearance. These results established that ZNF143 acts upstream of SMURF1 and TRPV1 in the same linear pathway: ZNF143 turns on SMURF1 transcription, SMURF1 ubiquitinates TRPV1 and targets it for degradation, and loss of TRPV1 suppresses mitophagy, leading to mitochondrial dysfunction and fat accumulation.

The significance of the finding is twofold. First, it adds to the emerging view that MASLD is fundamentally a disorder of impaired mitochondrial turnover, not simply one of excessive lipid synthesis. Multiple groups have shown that PINK1/Parkin-mediated mitophagy relieves fatty liver disease and that reversing Parkin-related mitophagy attenuates the condition. The current work identifies ZNF143 as a transcriptional switch that turns this quality control system off, providing a mechanistic explanation for why mitophagy declines during disease progression. Second, the study places TRPV1 — a channel best known from pain biology and dietary capsaicin research — at the centre of hepatic mitochondrial homeostasis. Recent work has implicated TRPV1 in mitophagy regulation in other contexts as well, including a 2025 report showing that TRPV1 inhibits both ferroptosis and mitophagy in heart failure through SFXN2, and a 2020 study showing that blocking TRPV1 promotes terminal mitophagy in multiple myeloma. The context-dependent role of TRPV1 in mitophagy across different tissues remains an open question, but the current study firmly establishes it as a downstream effector of ZNF143 in hepatocytes.

Therapeutically, the pathway offers several potential points of intervention. Small-molecule inhibitors of ZNF143 activity have already been developed for cancer applications, including YPC-21661 and YPC-22026, which were shown to inhibit ZNF143 activity both in vitro and in vivo. Inhibitors of SMURF1 have been designed for pulmonary arterial hypertension, suggesting that pharmacological tools against this E3 ligase could be repurposed for metabolic liver disease. Alternatively, TRPV1 agonists such as capsaicin or its analogues could theoretically compensate for the loss of TRPV1 protein caused by SMURF1-mediated degradation, consistent with epidemiological and experimental data suggesting that capsaicin may promote vascular and metabolic health. The authors note that the study’s findings, generated in mice and in a human hepatoma cell line, will need to be validated in human tissue samples and in additional model systems before any clinical translation.

The research was performed in accordance with guidelines approved by the Medical Ethics Committee of the First Affiliated Hospital of University of South China, and all authors declare no conflict of interest. The datasets generated and analysed during the study are available within the published article. As global rates of MASLD continue to climb in parallel with obesity and type 2 diabetes, identifying transcription factors such as ZNF143 that govern mitochondrial quality control provides a mechanistic framework for understanding disease progression and offers a roadmap for developing targeted therapies that restore the hepatocyte’s ability to clear its damaged mitochondria before steatosis spirals into inflammation, fibrosis and cancer.

At the core of the discussion is MASLD, a prevalent liver condition marked by abnormal fat accumulation in the liver coupled with metabolic dysfunction. It has gained notoriety as a significant public health concern globally. The disease spectrum encompasses a range of conditions, from simple steatosis to non-alcoholic steatohepatitis (NASH), cirrhosis, and even hepatocellular carcinoma. As lifestyle-related diseases proliferate, understanding MASLD’s implications on systemic health, particularly bone density, becomes increasingly relevant.

Bone health is an intricate interplay influenced by genetics, lifestyle, nutrition, and various health conditions. Osteoporosis emerges as one of the most common metabolic disorders, significantly impacting bone strength and increasing fragility fractures. The juxtaposition of these two conditions presents a multifaceted challenge, propelling researchers to investigate the potential interplay and disentangle the factors linking MASLD and osteoporosis.

The review meticulously compiles various studies, revealing disparate findings regarding the relationship between liver disease and bone health. Some evidence indicates that the inflammatory and metabolic changes associated with MASLD could negatively influence bone density and strength. Mechanistically, liver dysfunction can alter the metabolism of vitamin D and calcium, essential nutrients for bone health, potentially predisposing individuals to osteoporosis.

However, contrasting studies suggest that this relationship may not be straightforward. Certain individuals with MASLD exhibit preserved bone density, raising critical questions about predisposing factors and the biological mechanisms at play. Such variability could stem from genetic predispositions, lifestyle factors, dietary habits, and even variations in the disease’s progression. These inconsistencies underscore the nuanced and multifactorial nature of the relationship between these two seemingly disparate conditions.

Additionally, the review highlights potential mediators that might modify the relationship between MASLD and osteoporosis. Insulin resistance, often accompanying metabolic disorders, appears to be a crucial player in this ongoing saga. Insulin’s role in bone remodeling is increasingly recognized, raising the possibility that hyperinsulinemia characteristic of metabolic syndrome may directly affect bone health and contribute to decreased bone mineral density in affected individuals.

Furthermore, the review sheds light on the importance of sex and age as pivotal factors influencing this association. Women, particularly postmenopausal individuals, often experience accelerated bone loss due to estrogen deficiency. In conjunction with MASLD, this demographic may represent a particularly vulnerable cohort for osteoporosis, juxtaposing metabolic health and skeletal integrity.

Moreover, the interplay between lifestyle choices and MASLD cannot be overstated. Nutritional patterns, physical activity levels, and body composition significantly impact both conditions. The review emphasizes the need for comprehensive lifestyle interventions to mitigate both MASLD and osteoporosis risks concurrently, advocating for integrated approaches in clinical practice that prioritize metabolic health alongside skeletal well-being.

As researchers explore these intricate relationships, novel biomarkers and therapeutic targets are being identified, presenting exciting avenues for future research. Understanding the biological underpinnings of the MASLD-osteoporosis connection may yield innovative treatment strategies, potentially transforming clinical management for patients affected by both conditions.

This review, therefore, serves as a clarion call for collaborative research efforts aimed at elucidating this complex relationship. Multi-disciplinary approaches encompassing hepatology, endocrinology, and nutrition will be fundamental in deciphering the various layers of interactions and establishing robust clinical guidelines that address the intersectionality of MASLD and osteoporosis.

In the realm of public health, the implications of these findings extend far beyond individual patient care. The alarming rise in metabolic disorders necessitates a holistic approach to health intervention programs that emphasize prevention and risk mitigation. Policymakers must acknowledge the interconnected nature of these conditions, advocating for comprehensive health strategies that encompass lifestyle education, access to care, and multidisciplinary treatment modalities.

In summary, the contested association between MASLD and osteoporosis opens a Pandora’s box of possibilities and challenges. As clinicians strive to manage patients in an increasingly complex landscape of metabolic health, the insights garnered from this narrative review underscore the urgency to refine our understanding, elevate research priorities, and ultimately improve patient outcomes.

In conclusion, the intersection of MASLD and osteoporosis elucidates a compelling narrative fraught with contradictions yet rich in potential for scientific inquiry. As more nuanced understandings of these interconnected health concerns unfold, we stand on the precipice of transformative advancements that could dramatically reshape our approach to patient care in the ever-evolving landscape of metabolic health.

Subject of Research: The association between Metabolically Associated Steatotic Liver Disease (MASLD) and osteoporosis.

Article Title: The contested association between MASLD and osteoporosis: a narrative review of heterogeneous evidence and modifying factors.

Article References:

Xiao, YJ., Zhang, YL., Mao, XZ. et al. The contested association between MASLD and osteoporosis: a narrative review of heterogeneous evidence and modifying factors.
Arch Osteoporos 21, 22 (2026). https://doi.org/10.1007/s11657-025-01639-9

Image Credits: AI Generated

DOI: 10.1007/s11657-025-01639-9

Keywords: MASLD, osteoporosis, liver disease, metabolic health, bone density, insulin resistance, lifestyle interventions, public health.

Circadian rhythms regulate numerous biological processes, influencing everything from sleep patterns to metabolism. Deviation from these natural cycles, often triggered by lifestyle factors such as shift work, irregular sleep schedules, or frequent travel across time zones, can lead to serious health repercussions. Research has long highlighted the implications of circadian disruption on metabolic health, but clarity on the molecular mechanisms driving such conditions was lacking until now. This research lays the groundwork by meticulously detailing the pathways involved in the relationship between these seemingly disconnected areas.

The team employed a mouse model to study the effects of circadian disruptions on liver pathology, particularly focusing on the development of non-alcoholic fatty liver disease. This condition is characterized by excessive fat accumulation in liver cells, occurring in individuals who consume little to no alcohol. As the prevalence of NAFLD continues to rise globally, understanding its etiology has become urgent. The team’s findings underscore the correlation between altered circadian rhythms and increased susceptibility to this disease.

Through their experimental design, the researchers manipulated light-dark cycles to induce circadian disruption in test subjects. This strategic approach allowed them to observe significant physiological changes within the liver, including increased fat accumulation, liver inflammation, and the activation of specific death pathways within cells. These phenomena indicate that the liver is particularly sensitive to circadian misalignment, demonstrating how crucial timing is to its health and function.

Central to the findings is the activation of the RIPK1-RIPK3-MLKL cell death signaling axis. This signaling pathway has been implicated in various forms of cell death, including necroptosis—a regulated form of necrosis that can lead to significant tissue damage and inflammation. The study identified that circadian disruption activates this axis, contributing to hepatic inflammation and worsening the fatty liver pathology in the affected mice. This connection emphasizes the intricate relationship between our biological clocks and cellular health mechanisms.

Furthermore, the research delves into the specifics of how these signaling pathways engage following circadian disruption. Not only do they establish that RIPK1, RIPK3, and MLKL expression levels are affected, but they also illustrate the consequences of this altered expression on liver functional integrity. Key metabolic processes begin to fail, ultimately resulting in an accumulation of lipids, indicative of fatty liver disease. This detailed investigation provides a molecular basis for the observable physiological changes in NAFLD, paving the way for further exploration into treatment avenues.

The implications of these findings extend beyond the laboratory. For individuals facing circadian disruptions due to modern lifestyle demands, such as irregular work hours or excessive screen time before bed, this research serves as a timely warning about the potential health costs. Furthermore, it highlights the necessity for lifestyle adjustments and potential interventions that could mitigate circadian misalignment’s harmful effects on liver health—and by extension, overall metabolic health.

The study also raises questions about the potential for pharmacological intervention targeting the RIPK1-RIPK3-MLKL axis. If circadian disruptions contribute to the worsening of diseases through this specific pathway, therapeutics that modulate this signaling cascade could represent a novel approach to treat or prevent NAFLD. The researchers advocate for further exploration into compounds that may be able to address the effects of circadian misalignment on liver health and explore options that can synchronize biological rhythms.

Moreover, the research underscores the significance of public health messaging regarding the importance of maintaining regular sleep patterns and overall lifestyle harmony. As we increasingly recognize the complex relationship between our environments and our biological systems, interventions that promote better circadian alignment could have far-reaching implications for liver health and metabolic disorders at large.

In reviewing the study’s methodology, it is essential to acknowledge the rigor involved in conducting experiments using animal models. By meticulously syncing the disruptions with carefully monitored physiological responses, the research team was able to capture the nuances of how circadian rhythm interference can progressively aggravate liver disease pathology. This level of detail is critical for understanding the translational potential of these findings to human health concerns surrounding NAFLD.

In conclusion, this pioneering research underscores the vital interplay between our body clocks and the mechanisms underpinning liver disease. As circadian disruption becomes more prevalent in modern society, studies like these illuminate the urgency of identifying effective preventive measures for metabolic diseases like non-alcoholic fatty liver disease. By fostering a greater understanding of these interactions, researchers are positioning the medical community to devise informed strategies to promote better health outcomes for individuals living with the repercussions of altered circadian rhythms.

With future studies aimed at addressing the therapeutic potential of targeting the RIPK1-RIPK3-MLKL axis, we have reason to be optimistic about innovative solutions to combat NAFLD and enhance liver health—particularly in an era where maintaining a harmonious relationship with our biological clocks is increasingly challenging.

The unfolding narrative within this realm of biomedical research beautifully illustrates how fundamental aspects of our biology are intertwined with environmental influences. The findings not only contribute to the existing body of knowledge but also help pave the way for holistic health interventions that embrace both medical and lifestyle approaches to optimize liver health and prevent disease progression.

As this research captures the attention of the scientific community and the public alike, we must remain vigilant in addressing and promoting awareness of circadian health, ultimately leading to better prevention and management of non-alcoholic fatty liver disease.

Subject of Research: Circadian Disruption and Non-Alcoholic Fatty Liver Disease

Article Title: Circadian disruption aggravates non-alcoholic fatty liver disease by activating RIPK1-RIPK3-MLKL axis in mice.

Article References:

Li, X., Wang, L., Cheng, X. et al. Circadian disruption aggravates non-alcoholic fatty liver disease by activating RIPK1-RIPK3-MLKL axis in mice.
Sci Rep (2025). https://doi.org/10.1038/s41598-025-32711-6

Image Credits: AI Generated

DOI:

Keywords: Circadian Rhythm, Non-Alcoholic Fatty Liver Disease, RIPK1, RIPK3, MLKL, Cell Signaling, Metabolic Disorder.